Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is a conjugate vaccine used for active immunization to prevent invasive disease caused by Haemophilus influenzae type b (Hib) in children aged six weeks through four years. The vaccine contains purified polyribosyl-ribitol-phosphate (PRP) from Hib strain 20,752 covalently linked to tetanus toxoid protein, which enhances the immune response by converting the T-cell independent bacterial polysaccharide into a T-cell dependent antigen. This results in robust IgG antibody production and immunologic memory against Hib. It is administered intramuscularly as part of a primary series and booster schedule[1][3][5].
- Brand names
- Hiberix
- Other names
- Hib vaccineHaemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)PRP-T vaccine
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen.